Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Candel Therapeutics ( (CADL) ).
On October 14, 2025, Candel Therapeutics announced a $130 million term loan facility with Trinity Capital Inc., which includes an initial draw of $50 million. This strategic financing strengthens Candel’s financial position, enabling the initiation of a phase 3 clinical trial for CAN-2409 in non-small cell lung cancer and supporting potential commercialization efforts in early localized prostate cancer. Additionally, Candel reported positive interim data from its phase 1b clinical trial of CAN-3110 in recurrent glioblastoma, indicating promising survival outcomes. The company plans to focus its resources on advancing therapies for prostate cancer and NSCLC while seeking partnerships for CAN-2409’s development in pancreatic ductal adenocarcinoma.
The most recent analyst rating on (CADL) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page.
Spark’s Take on CADL Stock
According to Spark, TipRanks’ AI Analyst, CADL is a Underperform.
Candel Therapeutics is currently facing substantial financial challenges with no revenue and ongoing cash burn, which heavily weighs down its stock score. Despite positive clinical trial results offering future potential, the current technical and valuation metrics remain unfavorable, reflecting the speculative nature of the stock.
To see Spark’s full report on CADL stock, click here.
More about Candel Therapeutics
Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus gene constructs, with CAN-2409 and CAN-3110 as lead product candidates.
Average Trading Volume: 780,928
Technical Sentiment Signal: Strong Buy
Current Market Cap: $339.8M
See more insights into CADL stock on TipRanks’ Stock Analysis page.